# Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Source: https://onco.cc/trials/nct03003962/  
OnCo record `nct03003962` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) is a phase 3 interventional study registered as NCT03003962 by AstraZeneca, with 669 participants enrolled, started 2017-01-02 and due to reach its primary completion in 2022-10-27. Interventions recorded: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: PEARL
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03003962
- Phase: 3
- Setting: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer
- Sponsor: AstraZeneca
- Enrolled: 669
- Outcomes: Overall Survival (OS): Durvalumab 14.6 months vs Platinum-based SoC 12.8 months, HR 0.84; OS in Participants With LREM: Durvalumab 14.6 months vs Platinum-based SoC 15 months, HR 0.96; Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment: Durvalumab 37.6% vs Platinum-based SoC 37.4%

## Sources

- ClinicalTrials.gov NCT03003962: https://clinicaltrials.gov/study/NCT03003962

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study](https://onco.cc/key-papers/paper-nct03003962-j-thorac-oncol-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct03003962.json